TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was founded in 2004, formerly known as Lexington Pharmaceuticals, Inc., and changed to its current name in March 2005. Headquartered in San Diego, California, with 24 full-time employees, it is a clinical-stage company A biopharmaceutical company focused on the development and commercialization of treatments for cancer, wet age-related macular degeneration (AMD) and fibrotic diseases.
TRACON Pharmaceuticals, Inc. (TCON):
TRACON Pharmaceuticals’ clinical stage products include:
TRACON Pharmaceuticals’ main product candidate TRC105 , an endoglin antibody, is undergoing a phase III clinical trial for the treatment of angiosarcoma; a randomized phase II clinical trial for the treatment of renal cell carcinoma; a phase II clinical trial for gestational trophoblastic tumors; liver Phase I/II clinical trials for cell carcinoma; Phase I clinical trials for the treatment of lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; Randomized phase II clinical trials for wet age-related macular degeneration.
TRACON Pharmaceuticals’ product candidates also include TRC102 , a small molecule, in a phase II clinical trial for the treatment of mesothelioma; a phase II clinical trial for the treatment of glioblastoma; a phase I clinical trial for the treatment of solid tumors; for solid tumors and Phase I/II clinical trials for the treatment of lymphoma; and Phase I clinical trials for the treatment of lung cancer.
TRACON Pharmaceuticals is also developing TRC253 , a small molecule competitive inhibitor with high affinity for androgen receptor (AR) and multiple AR variants, which is currently in phase I/II clinical trials for the treatment of prostate cancer.
TRACON Pharmaceuticals’ pre-clinical products include: TRC694 , an oral bioavailable NF-kB-induced kinase inhibitor for the treatment of hematological malignancies, including myeloma.
TRACON Pharmaceuticals, Inc. and Ambrx, Inc. have signed a license agreement to develop and commercialize TRC105 ; cooperate with Santen Pharmaceutical Co., Ltd to develop, manufacture and commercialize DE-122 for the ophthalmic indications of TRC105; and with Janssen Pharmaceutica NV signed a strategic license agreement to jointly develop TRC253 and TRC694.
TRACON Pharmaceuticals, Inc. (TCON) investment:
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) had an IPO on 1/30/2015 with an issue price of US$10, issuing 3.6 million shares and raising US$36 million.